Literature DB >> 24583705

Density of tumor-infiltrating FOXP3+ T cells as a response marker for induction chemoradiotherapy and a potential prognostic factor in patients treated with trimodality therapy for locally advanced non-small cell lung cancer.

Hiroyuki Tao1, Kazuhiko Shien, Junichi Soh, Eisuke Matsuda, Shinichi Toyooka, Kazunori Okabe, Shinichiro Miyoshi.   

Abstract

PURPOSE: To examine the relationship between the density of tumor-infiltrating T cell subpopulations and the pathological response to induction chemoradiotherapy (CRT) in patients with locally advanced NSCLC, and to assess the impact of T cell density on patient prognosis.
METHODS: A total of 64 patients with c-stages IIA-IIIB NSCLC who underwent induction CRT followed by R0 surgery were enrolled. Tumor-infiltrating T cells expressing either FOXP3 or CD8 were detected by immunohistochemical staining.
RESULTS: Mean numbers of tumor-infiltrating FOXP3+ T cells were 39.9 for patients with minor pathological responses (n = 9), 18.4 for those with major pathological responses (n = 25), and 12.9 for those with complete pathological responses (n = 30; P <0.001). The number of CD8+ T cells was not associated with pathological responses. Patients with lower FOXP3+ T cell densities showed better survival, although the difference was not statistically significant.
CONCLUSION: Our study demonstrated that the density of tumor-infiltrating FOXP3+ T cells indicated the degree of response for induction CRT and prognosis in patients treated with trimodality therapy for locally advanced NSCLC, suggesting that FOXP3+ T cells may be target for adjunct immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24583705     DOI: 10.5761/atcs.oa.13-00237

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  6 in total

1.  Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients.

Authors:  Hans Van Hulle; Vincent Vakaet; Giselle Post; Annick Van Greveling; Chris Monten; An Hendrix; Koen Van de Vijver; Jo Van Dorpe; Pieter De Visschere; Geert Braems; Katrien Vandecasteele; Hannelore Denys; Wilfried De Neve; Liv Veldeman
Journal:  Pilot Feasibility Stud       Date:  2020-10-10

2.  PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.

Authors:  Malaka Ameratunga; Khashayar Asadi; Xihui Lin; Marzena Walkiewicz; Carmel Murone; Simon Knight; Paul Mitchell; Paul Boutros; Thomas John
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

3.  Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer.

Authors:  Dong-Qiang Zeng; Yun-Fang Yu; Qi-Yun Ou; Xiao-Yin Li; Ru-Zhi Zhong; Chuan-Miao Xie; Qiu-Gen Hu
Journal:  Oncotarget       Date:  2016-03-22

4.  FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer.

Authors:  Shucai Yang; Yi Liu; Ming-Yue Li; Calvin S H Ng; Sheng-Li Yang; Shanshan Wang; Chang Zou; Yujuan Dong; Jing Du; Xiang Long; Li-Zhong Liu; Innes Y P Wan; Tony Mok; Malcolm J Underwood; George G Chen
Journal:  Mol Cancer       Date:  2017-07-17       Impact factor: 27.401

5.  Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.

Authors:  Chao Liu; Qinyong Hu; Kai Hu; Huichao Su; Fang Shi; Li Kong; Hui Zhu; Jinming Yu
Journal:  J Transl Med       Date:  2019-04-11       Impact factor: 5.531

6.  A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma.

Authors:  Tian-En Li; Ze Zhang; Yi Wang; Da Xu; Jian Dong; Ying Zhu; Zheng Wang
Journal:  J Cancer       Date:  2021-03-15       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.